Does the media favor ALXO or LXRX?

In the previous week, Lexicon Pharmaceuticals had 17 more articles in the media than ALX Oncology. MarketBeat recorded 21 mentions for Lexicon Pharmaceuticals and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Lexicon Pharmaceuticals' score of 0.07 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CGEM or ALXO?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is CGEM or ALXO more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% ALX Oncology N/A -90.30% -67.28%

Does the media prefer CGEM or ALXO?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Cullinan Therapeutics' score of 0.16 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, OLMA or ALXO?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is OLMA or ALXO more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% ALX Oncology N/A -90.30% -67.28%

Does the media refer more to OLMA or ALXO?

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 4 articles in the media. ALX Oncology's average media sentiment score of 0.71 beat Olema Pharmaceuticals' score of 0.58 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, JBIO or ALXO?

Jade Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$2.02 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is JBIO or ALXO more profitable?

Jade Biosciences' return on equity of -51.34% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -51.34% -47.32% ALX Oncology N/A -90.30% -67.28%

Does the media refer more to JBIO or ALXO?

In the previous week, Jade Biosciences and Jade Biosciences both had 4 articles in the media. Jade Biosciences' average media sentiment score of 1.12 beat ALX Oncology's score of 0.71 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALXO or AVTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% Avalo Therapeutics N/A -58.03% -48.22%

Does the media prefer ALXO or AVTX?

In the previous week, Avalo Therapeutics had 7 more articles in the media than ALX Oncology. MarketBeat recorded 11 mentions for Avalo Therapeutics and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Avalo Therapeutics' score of -0.21 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

ALX Oncology (ALXO) Competitors

$2.12 +0.02 (+0.71%)

As of 11:09 AM Eastern

Compare

ALXO vs. LXRX, CGEM, OLMA, JBIO, and AVTX

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include Lexicon Pharmaceuticals (LXRX), Cullinan Therapeutics (CGEM), Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO), and Avalo Therapeutics (AVTX). These companies are all part of the "biotechnology" industry.

How does ALX Oncology compare to Lexicon Pharmaceuticals?

ALX Oncology (NASDAQ:ALXO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Lexicon Pharmaceuticals had 17 more articles in the media than ALX Oncology. MarketBeat recorded 21 mentions for Lexicon Pharmaceuticals and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Lexicon Pharmaceuticals' score of 0.07 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 117.49%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 87.63%. Given ALX Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe ALX Oncology is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lexicon Pharmaceuticals has higher revenue and earnings than ALX Oncology. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Lexicon Pharmaceuticals	$49.80M	21.67	-$50.34M	-$0.15	N/A

ALX Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

ALX Oncology has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Lexicon Pharmaceuticals beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Cullinan Therapeutics' return on equity of -52.89% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
ALX Oncology	N/A	-90.30%	-67.28%

In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Cullinan Therapeutics' score of 0.16 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 12.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics currently has a consensus price target of $32.14, indicating a potential upside of 76.60%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 117.49%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts plainly believe ALX Oncology is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ALX Oncology beats Cullinan Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Olema Pharmaceuticals has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals and Olema Pharmaceuticals both had 4 articles in the media. ALX Oncology's average media sentiment score of 0.71 beat Olema Pharmaceuticals' score of 0.58 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals currently has a consensus price target of $44.10, suggesting a potential upside of 263.02%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 117.49%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Olema Pharmaceuticals' return on equity of -46.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
ALX Oncology	N/A	-90.30%	-67.28%

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Summary

Olema Pharmaceuticals beats ALX Oncology on 7 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Jade Biosciences has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Jade Biosciences' return on equity of -51.34% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
ALX Oncology	N/A	-90.30%	-67.28%

Jade Biosciences is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Jade Biosciences currently has a consensus price target of $51.57, indicating a potential upside of 130.60%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 117.49%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Jade Biosciences is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Jade Biosciences and Jade Biosciences both had 4 articles in the media. Jade Biosciences' average media sentiment score of 1.12 beat ALX Oncology's score of 0.71 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.0% of ALX Oncology shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Jade Biosciences beats ALX Oncology on 9 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Avalo Therapeutics?

ALX Oncology (NASDAQ:ALXO) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Avalo Therapeutics' return on equity of -58.03% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Avalo Therapeutics has higher revenue and earnings than ALX Oncology. Avalo Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Avalo Therapeutics	$60K	17,139.25	-$78.26M	-$4.37	N/A

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 117.49%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 135.20%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 12.4% of ALX Oncology shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Avalo Therapeutics had 7 more articles in the media than ALX Oncology. MarketBeat recorded 11 mentions for Avalo Therapeutics and 4 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.71 beat Avalo Therapeutics' score of -0.21 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Summary

Avalo Therapeutics beats ALX Oncology on 9 of the 14 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$283.25M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.86	9.06	269.91	24.87
Price / Sales	N/A	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	4.41	17.97	11.40	6.45
Net Income	-$101.69M	-$13.25M	$3.45B	$347.50M
7 Day Performance	9.59%	5.58%	3.66%	3.77%
1 Month Performance	-0.70%	-1.60%	-0.49%	-0.40%
1 Year Performance	212.50%	61.32%	77.51%	23.55%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	2.2834 of 5 stars	$2.12 +0.7%	$4.60 +117.5%	+210.3%	$283.25M	N/A	N/A	40	Earnings Report
LXRX Lexicon Pharmaceuticals	1.5065 of 5 stars	$2.33 +0.9%	$4.55 +95.3%	+128.7%	$1.03B	$49.80M	N/A	140	Earnings Report Analyst Downgrade Analyst Revision
CGEM Cullinan Therapeutics	2.6853 of 5 stars	$16.25 -1.5%	$32.14 +97.8%	+142.9%	$1.01B	N/A	N/A	30	Earnings Report
OLMA Olema Pharmaceuticals	2.0082 of 5 stars	$11.28 -1.5%	$44.10 +291.0%	+159.7%	$1.00B	N/A	N/A	70	Gap Up
JBIO Jade Biosciences	3.2935 of 5 stars	$19.15 -3.0%	$51.57 +169.3%	+193.2%	$974.86M	N/A	N/A	20	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. LXRX, CGEM, OLMA, JBIO, and AVTX

How does ALX Oncology compare to Lexicon Pharmaceuticals?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Summary

How does ALX Oncology compare to Olema Pharmaceuticals?

Summary

How does ALX Oncology compare to Jade Biosciences?

Summary

How does ALX Oncology compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. LXRX, CGEM, OLMA, JBIO, and AVTX

How does ALX Oncology compare to Lexicon Pharmaceuticals?

Does the media favor ALXO or LXRX?

Do institutionals & insiders have more ownership in ALXO or LXRX?

Do analysts prefer ALXO or LXRX?

Which has preferable valuation and earnings, ALXO or LXRX?

Which has more volatility and risk, ALXO or LXRX?

Is ALXO or LXRX more profitable?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Is CGEM or ALXO more profitable?

Does the media prefer CGEM or ALXO?

Which has more risk and volatility, CGEM or ALXO?

Which has stronger valuation & earnings, CGEM or ALXO?

Do institutionals & insiders believe in CGEM or ALXO?

Do analysts prefer CGEM or ALXO?

Summary

How does ALX Oncology compare to Olema Pharmaceuticals?

Which has more volatility and risk, OLMA or ALXO?

Do institutionals and insiders have more ownership in OLMA or ALXO?

Does the media refer more to OLMA or ALXO?

Do analysts recommend OLMA or ALXO?

Is OLMA or ALXO more profitable?

Which has stronger earnings and valuation, OLMA or ALXO?

Summary

How does ALX Oncology compare to Jade Biosciences?

Which has more volatility and risk, JBIO or ALXO?

Is JBIO or ALXO more profitable?

Which has preferable valuation & earnings, JBIO or ALXO?

Do analysts rate JBIO or ALXO?

Does the media refer more to JBIO or ALXO?

Do institutionals and insiders believe in JBIO or ALXO?

Summary

How does ALX Oncology compare to Avalo Therapeutics?

Is ALXO or AVTX more profitable?

Which has better valuation & earnings, ALXO or AVTX?

Do analysts prefer ALXO or AVTX?

Do insiders and institutionals have more ownership in ALXO or AVTX?

Does the media prefer ALXO or AVTX?

Which has more risk and volatility, ALXO or AVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools